Preclinical safety

14/04/202507/04/2026News

Allegro demonstrates safety profile of osteoarthritis hydrogel in data presentation at World Congress on Osteoporosis

Liege, Belgium – 11 April 2025 (17:00 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]

25/03/202507/04/2026News

Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies

Liege, Belgium – 25 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]

04/03/202522/04/2026News

Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies

Allegro updated this press release on April 20, 2026, to refine certain statements in accordance with regulatory guidelines Liege, Belgium – 4 […]

11/12/202422/04/2026News

Allegro’s osteoarthritis injectable shock absorbing gel demonstrates preclinical safety

Allegro updated this press release on April 20, 2026, to refine certain statements in accordance with regulatory guidelines Liege, Belgium – 11 […]